On Mar. 23, 2020, Acura Pharmaceuticals announced that Abuse Deterrent Pharma, its licensee of LTX-03 (Hydrocodone Bitartrate and Acetaminophen with Acuraﾒs LIMITxﾙ Technology), has engaged Catalent Pharma Solutions to perform tablet manufacturing for clinical testing supplies of the product. Acura previously engaged Catalent to perform micro-particle process development for LTX-03 using hot-melt extrusion technology at Catalentﾒs Somerset, New Jersey facility before transferring to scaled production in Winchester, Kentucky, and which work is pending receipt of auxiliary manufacturing equipment expected in the next 30 days.